Selumetinib联合达卡巴嗪治疗转移性葡萄膜黑色素瘤的III期随机试验(SUMIT)
SUMIT是一项III期双盲随机试验,纳入129例未接受过系统治疗的转移性葡萄膜黑色素瘤患者,按3:1随机接受selumetinib联合达卡巴嗪或安慰剂联合达卡巴嗪。联合方案安全性可耐受,但未显著改善PFS。
要点
- Selumetinib联合达卡巴嗪未显著改善转移性葡萄膜黑色素瘤的PFS。
- 常见不良事件为恶心、皮疹、疲劳、腹泻和外周水肿,联合组发生率更高。
核心结论
- 在转移性葡萄膜黑色素瘤患者中,selumetinib联合达卡巴嗪安全性可耐受,但未较安慰剂联合达卡巴嗪显著改善PFS。
研究设计与样本
- SUMIT为III期双盲随机试验(NCT01974752),纳入129例未接受过系统治疗的转移性葡萄膜黑色素瘤患者,按3:1随机分配至selumetinib(75 mg每日两次)联合达卡巴嗪(1,000 mg/m2静脉第1天,每21天周期)组(n=97)或安慰剂联合达卡巴嗪组(n=32)。
主要发现
- 最常见不良事件(selumetinib联合达卡巴嗪 vs 安慰剂联合达卡巴嗪)包括恶心(62% vs 19%)、皮疹(57% vs 6%)、疲劳(44% vs 47%)、腹泻(44% vs 22%)和外周水肿(43% vs 6%)。
临床怎么用
- 对于转移性葡萄膜黑色素瘤且未接受过系统治疗的患者,selumetinib联合达卡巴嗪不推荐作为优于达卡巴嗪单药的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial. Methods The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial ( ClinicalTrial.gov identifier: NCT01974752) in which patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine. The primary end point was progression-free survival (PFS) by blinded independent central radiologic review. Secondary end points included overall survival and objective response rate. Results A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32). In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32). The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36). At 37% maturity (n = 48 deaths), analysis of overall survival gave a hazard ratio of 0.75 (95% CI, 0.39 to 1.46; two-sided P = .40). The most frequently reported adverse events (selumetinib plus dacarbazine v placebo plus dacarbazine) were nausea (62% v 19%), rash (57% v 6%), fatigue (44% v 47%), diarrhea (44% v 22%), and peripheral edema (43% v 6%). Conclusion In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.
引用
- Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). J Clin Oncol. 2018. PMID: 29528792. doi:10.1200/JCO.2017.74.1090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。